Industry Strength Score
65/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
RELMADA THERAPEUTICS INC (RLMD) Stock Price & Overview
NASDAQ:RLMD • US75955J4022
Current stock price
7.32 USD
+0.08 (+1.1%)
Last:
The current stock price of RLMD is 7.32 USD. Today RLMD is up by 1.1%. In the past month the price increased by 13.48%. In the past year, price increased by 1883.02%.
RLMD Key Statistics
52-Week Range0.3233 - 7.94
Current RLMD stock price positioned within its 52-week range.
1-Month Range6.375 - 7.94
Current RLMD stock price positioned within its 1-month range.
- Market Cap
- 767.795M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.47
- Dividend Yield
- N/A
RLMD Stock Performance
Today
+1.1%
1 Week
+1.40%
1 Month
+13.48%
3 Months
+103.94%
Longer-term
6 Months +220.35%
1 Year +1,883.02%
2 Years +98.90%
3 Years +187.30%
5 Years -81.22%
10 Years N/A
RLMD Stock Chart
RLMD Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to RLMD. When comparing the yearly performance of all stocks, RLMD is one of the better performing stocks in the market, outperforming 99.86% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
RLMD Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RLMD. No worries on liquidiy or solvency for RLMD as it has an excellent financial health rating, but there are worries on the profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
RLMD Earnings
Next Earnings DateMay 13, 2026
Last Earnings DateMar 19, 2026
PeriodQ4 / 2025
EPS Reported-$0.29
Revenue Reported
EPS Surprise -103.08%
Revenue Surprise %
RLMD Forecast & Estimates
11 analysts have analysed RLMD and the average price target is 14.03 USD. This implies a price increase of 91.6% is expected in the next year compared to the current price of 7.32.
Analysts
Analysts85.45
Price Target14.03 (91.67%)
EPS Next Y47.27%
Revenue Next YearN/A
RLMD Financial Highlights
Over the last trailing twelve months RLMD reported a non-GAAP Earnings per Share(EPS) of -1.47. The EPS increased by 44.53% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-57.39M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -61.05% | ||
| ROE | -66.33% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%53.23%
Sales Q2Q%N/A
EPS 1Y (TTM)44.53%
Revenue 1Y (TTM)N/A
RLMD Ownership
Ownership
Inst Owners48.56%
Shares104.89M
Float94.31M
Ins Owners4.68%
Short Float %6.57%
Short Ratio3.01
RLMD Industry Overview
RLMD operates in the Pharmaceuticals sub-industry within the Health Care sector. This group contains 135 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
17/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
62%
Outperformed 62% of sub-industries
3 Month Rank
47%
Outperformed 47% of sub-industries
6 Month Rank
37%
Outperformed 37% of sub-industries
Industry Fundamentals & Breadth
- Members
- 135
- New Highs
- 4.4%
- New Lows
- 4.4%
- Average ROE
- 50.6%
- Average Profit Margin
- 27.8%
- Average Operating Margin
- 37.5%
- Average P/E
- 25.4
- Average Fwd P/E
- 20.0
- Average Debt/Equity
- 1.2
RLMD Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 24.35 | 825.773B | ||
| JNJ | JOHNSON & JOHNSON | 17.78 | 548.657B | ||
| MRK | MERCK & CO. INC. | 21.52 | 271.761B | ||
| PFE | PFIZER INC | 8.81 | 150.628B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.13 | 118.952B | ||
| ZTS | ZOETIS INC | 16.11 | 49.054B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.7 | 28.582B | ||
| VTRS | VIATRIS INC | 6.02 | 17.257B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 20.79 | 11.061B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.463B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.11B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.955B | ||
| CORT | CORCEPT THERAPEUTICS INC | 86.83 | 4.959B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About RLMD
Company Profile
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. The company is headquartered in Coral Gables, Florida and currently employs 17 full-time employees. The company went IPO on 2014-03-03. The firm is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of CNS diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Its lead product candidate, esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications. Sepranolone is its phase IIb ready neurosteroid developed for the potential treatment of Tourette syndrome and other compulsive disorders.
Company Info
IPO: 2014-03-03
RELMADA THERAPEUTICS INC
2222 Ponce De Leon Blvd. 3Rd Floor
Coral Gables FLORIDA 10022 US
CEO: Sergio Traversa
Employees: 17
Phone: 16468763459
RELMADA THERAPEUTICS INC / RLMD FAQ
What does RLMD do?
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. The company is headquartered in Coral Gables, Florida and currently employs 17 full-time employees. The company went IPO on 2014-03-03. The firm is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of CNS diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Its lead product candidate, esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications. Sepranolone is its phase IIb ready neurosteroid developed for the potential treatment of Tourette syndrome and other compulsive disorders.
Can you provide the latest stock price for RELMADA THERAPEUTICS INC?
The current stock price of RLMD is 7.32 USD. The price increased by 1.1% in the last trading session.
What is the dividend status of RELMADA THERAPEUTICS INC?
RLMD does not pay a dividend.
What is the ChartMill technical and fundamental rating of RLMD stock?
RLMD has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is RELMADA THERAPEUTICS INC (RLMD) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on RLMD.
What is RELMADA THERAPEUTICS INC worth?
RELMADA THERAPEUTICS INC (RLMD) has a market capitalization of 767.79M USD. This makes RLMD a Small Cap stock.
Can you provide the upcoming earnings date for RELMADA THERAPEUTICS INC?
RELMADA THERAPEUTICS INC (RLMD) will report earnings on 2026-05-13.